Get a Demo

8 min read

An Overview of ICH Guidelines

Featured Image

Last Updated: October 2026

What are ICH guidelines? They are the harmonised technical standards for developing and registering medicines that the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) publishes. They fall into four series: Quality (Q), Safety (S), Efficacy (E) and Multidisciplinary (M). ICH guidelines are not law on their own, but regulators such as the FDA and EMA implement them, so following them is the practical route to a submission that is accepted across regions. The current Good Clinical Practice standard is ICH E6(R3).

Each country or region's regulatory authority (the FDA in the US, the EMA in Europe, Health Canada, and others) sets its own requirements for clinical research. Many trials recruit across borders and the resulting treatment is eventually distributed across them. By standardizing technical requirements, ICH aims to improve the efficiency and safety of drug development worldwide. Below, we walk through each of the four series, what the current guideline codes cover, and where the status of a guideline has recently changed.

In this guide:

The four ICH guideline categories

ICH organizes its guidelines under four topic codes: Q for Quality, S for Safety, E for Efficacy and M for Multidisciplinary. Quality covers manufacturing and product quality, Safety covers nonclinical studies, Efficacy covers the design, conduct, safety and reporting of clinical trials, and Multidisciplinary covers topics that cut across the other three. Each guideline carries a code (such as E6) and, when revised, a revision tag (such as R3). The tables below list every current guideline and its status as published by ICH in October 2026.

Quality guidelines (Q)

Quality guidelines cover quality control throughout the drug development lifecycle, so that pharmaceutical products are consistently safe, effective and of high quality. Topics include stability studies, impurity testing, analytical validation, and flexible, risk-based approaches built on Good Manufacturing Practice (GMP). For a closer look at one of the most-used documents in the series, see our guide to ICH Q9 quality risk management.

The current Quality guidelines are outlined as follows:

CodeTitleStatus (per ICH)
Q1Stability Testing of Drug Substances and Drug Products (Q1A(R2)–Q1E; Q1F withdrawn)Consolidated Q1 revision in draft (Step 2b, April 2025)
Q2(R2)Validation of Analytical ProceduresStep 4, November 2023
Q3A(R2) – Q3EImpurities: new drug substances (Q3A), new drug products (Q3B), residual solvents (Q3C(R9)), elemental impurities (Q3D(R2)), extractables and leachables (Q3E)Q3C(R9) Step 4 January 2024; Q3E in draft (Step 2b, August 2025)
Q4A – Q4BPharmacopoeias, including evaluation and recommendation of pharmacopoeial texts (Q4B(R1))Q4B(R1) Step 4, June 2024
Q5A(R2) – Q5EQuality of biotechnological products, from viral safety (Q5A(R2)) to comparability after manufacturing changes (Q5E)Q5A(R2) Step 4, November 2023
Q6A, Q6BSpecifications: test procedures and acceptance criteria for chemical and biotechnological/biological productsStep 4 (1999)
Q7Good Manufacturing Practice for Active Pharmaceutical IngredientsStep 4, November 2000
Q8(R2)Pharmaceutical DevelopmentStep 4, August 2009
Q9(R1)Quality Risk ManagementStep 4, January 2023
Q10Pharmaceutical Quality SystemStep 4, June 2008
Q11Development and Manufacture of Drug SubstancesStep 4, May 2012
Q12Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle ManagementStep 4, November 2019
Q13Continuous Manufacturing of Drug Substances and Drug ProductsStep 4, November 2022
Q14Analytical Procedure DevelopmentStep 4, November 2023

Safety guidelines (S)

Safety guidelines are designed to uncover potential risks before a product reaches people, such as carcinogenicity, genotoxicity, reproductive toxicity and effects on the heart's electrical activity. They define which nonclinical studies support the move into human trials and later registration.

The current Safety guidelines are outlined as follows:

CodeTitleStatus (per ICH)
S1A, S1B(R1), S1C(R2)Carcinogenicity: need for studies (S1A), testing (S1B(R1)) and dose selection (S1C(R2))S1B(R1) Step 4, August 2022
S2(R1)Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human UseStep 4, November 2011
S3A, S3BToxicokinetics (S3A) and repeated-dose tissue distribution studies (S3B)Step 4, October 1994
S4Duration of Chronic Toxicity Testing in Animals (Rodent and Non-Rodent)Step 4, September 1998
S5(R3)Detection of Toxicity to Reproduction for Human PharmaceuticalsStep 4, February 2020
S6(R1)Preclinical Safety Evaluation of Biotechnology-Derived PharmaceuticalsStep 4, June 2011
S7A, S7BSafety Pharmacology Studies (S7A) and non-clinical evaluation of delayed ventricular repolarization, or QT prolongation (S7B)S7B Step 4, May 2005
S8Immunotoxicity Studies for Human PharmaceuticalsStep 4, September 2005
S9Nonclinical Evaluation for Anticancer PharmaceuticalsStep 4, November 2009
S10Photosafety Evaluation of PharmaceuticalsStep 4, November 2013
S11Nonclinical Safety Testing in Support of Development of Paediatric MedicinesStep 4, April 2020
S12Nonclinical Biodistribution Considerations for Gene Therapy ProductsStep 4, March 2023

Efficacy guidelines (E) and ICH E6(R3)

Efficacy guidelines concern the design, conduct, safety and reporting of clinical trials. They also cover medicines derived from biotechnological processes and the use of pharmacogenetics and genomics to produce better-targeted medicines. This series includes the pharmacovigilance E2 family and the statistical principles in E9.

The current Efficacy guidelines are outlined as follows:

CodeTitleStatus (per ICH)
E1The Extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-Term Treatment of Non-Life-Threatening ConditionsStep 4, 1994
E2A – E2FClinical safety data management and pharmacovigilance: expedited reporting (E2A), ICSR data elements (E2B(R3)), periodic benefit-risk evaluation reports (E2C(R2)), post-approval safety data (E2D(R1)), pharmacovigilance planning (E2E) and development safety update reports (E2F)E2D(R1) Step 4, September 2025
E3Structure and Content of Clinical Study ReportsStep 4, 1995
E4Dose-Response Information to Support Drug RegistrationStep 4, 1994
E5(R1)Ethnic Factors in the Acceptability of Foreign Clinical DataStep 4, 1998
E6(R3)Good Clinical Practice (GCP)Principles and Annex 1 adopted 6 January 2025; Annex 2 adopted 3 June 2026
E7Studies in Support of Special Populations: GeriatricsStep 4, 1993
E8(R1)General Considerations for Clinical StudiesStep 4, October 2021
E9, E9(R1)Statistical Principles for Clinical Trials, with the estimands addendumAddendum Step 4, November 2019
E10Choice of Control Group and Related Issues in Clinical TrialsStep 4, 2000
E11(R1), E11AClinical investigation of medicinal products in the paediatric population (E11(R1)) and paediatric extrapolation (E11A)E11A Step 4, August 2024
E12Principles for Clinical Evaluation of New Antihypertensive Drugs—
E14The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic DrugsStep 4, May 2005
E15Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding CategoriesStep 4, November 2007
E16Biomarkers Related to Drug or Biotechnology Product Development: Context, Structure and Format of Qualification SubmissionsStep 4, August 2010
E17General Principles for Planning and Design of Multi-Regional Clinical TrialsStep 4, November 2017
E18Genomic Sampling and Management of Genomic DataStep 4, September 2017
E19A Selective Approach to Safety Data Collection in Specific Late-Stage Pre-approval or Post-Approval Clinical TrialsStep 4, September 2022
E20Adaptive Designs for Clinical TrialsDraft (Step 2b, June 2025)
E21Inclusion of Pregnant and Breastfeeding Individuals in Clinical TrialsDraft (Step 2b, May 2025)
E22General Considerations for Patient Preference StudiesDraft (Step 2b, October 2025)
E23Considerations for the Use of Real-World Evidence (RWE) to Inform Regulatory Decision MakingIn development

Note: there is no E13.

Good Clinical Practice: ICH E6(R3)

Among ICH's guidelines, Good Clinical Practice (GCP), code E6, is the fundamental standard for conducting clinical trials. It sets out the ethical and scientific standards for designing, conducting, recording and reporting trials involving human participants, protecting their rights, safety and well-being while keeping the resulting data credible.

ICH E6 is no longer in draft. According to ICH, the E6(R3) guideline was adopted in two stages: the Principles and Annex 1, a flexible, risk-based framework for interventional clinical trials, reached Step 4 on 6 January 2025, and Annex 2 was adopted on 3 June 2026. ICH is making Annex 2 available as a standalone document only through the end of 2026. For practical implementation detail, see our webinar on implementing ICH E6(R3). For the records side of GCP, see our guide to aligning eTMF with the CDISC TMF Reference Model.

Multidisciplinary guidelines (M)

Multidisciplinary guidelines are a catch-all for topics that do not fall into Quality, Safety or Efficacy, including medical terminology (MedDRA), the Common Technical Document (CTD), and electronic standards for the transfer of regulatory information (ESTRI). Several recent additions, including M11, M14 and M15, extend this series into protocol templates, real-world data and model-informed drug development.

The current Multidisciplinary guidelines are outlined as follows:

CodeTitleStatus (per ICH)
M1MedDRA: Medical Dictionary for Regulatory ActivitiesIn use since 1999
M2Electronic Standards for the Transfer of Regulatory Information (ESTRI)—
M3(R2)Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for PharmaceuticalsStep 4, June 2009
M4The Common Technical Document (CTD) for the registration of pharmaceuticals for human use, organised into quality, safety and efficacy parts—
M5Data Elements and Standards for Drug Dictionaries—
M6Virus and Gene Therapy Vector Shedding and TransmissionIn development
M7(R2)Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic RiskStep 4, April 2023
M8Electronic Common Technical Document (eCTD), including v3.2.2 and v4.0eCTD v4.0 in rollout
M9Biopharmaceutics Classification System-based BiowaiversStep 4, November 2019
M10Bioanalytical Method Validation and Study Sample AnalysisStep 4, May 2022
M11Clinical electronic Structured Harmonised Protocol (CeSHarP): protocol template and technical specificationStep 4, November 2025
M12Drug Interaction StudiesStep 4, May 2024
M13A – M13CBioequivalence for immediate-release solid oral dosage formsM13A Step 4, July 2024; M13C in development
M14General Principles on Plan, Design, Analysis, and Reporting of Non-Interventional Studies That Utilize Real-World Data for Safety Assessment of MedicinesStep 4, September 2025
M15General Principles for Model-Informed Drug DevelopmentStep 4, January 2026
M16, M18Structured Product Quality Submissions (M16); framework for determining the utility of comparative efficacy studies in biosimilar development (M18)In development

Of note: eCTD v4.0 has been rolling out over the past few years. For an in-depth look at the updates, read our article “Everything You Need to Know about eCTD 4.0”.

Are ICH guidelines mandatory?

ICH guidelines are not law by themselves, because ICH has no enforcement power. They become binding expectations when a regulatory authority implements them through its own regulation or guidance. ICH publishes an implementation status for each guideline, regulator by regulator, with dates; for example, its page for E1 shows the European Commission and the FDA among the regulators that have implemented it.

In practice, non-compliance with ICH guidelines can raise concerns during regulatory inspections and approvals, and adherence demonstrates a commitment to best practice and strengthens the credibility of clinical trial data. Teams should check how each guideline has been implemented by the regulators they file with, rather than assuming it applies the same way everywhere.

How to cite ICH guidelines

Proper citation acknowledges the source and keeps regulatory standards traceable. In academic or regulatory documents, the American Psychological Association (APA) style works well. The following format can be used:

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (Year of publication). Title of Guideline (ICH Guideline No.). Retrieved from URL

For example:

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1996). Good Clinical Practice (ICH E6). Retrieved from https://database.ich.org/sites/default/files/E6_R1_Guideline.pdf

When citing a guideline that has been revised, cite the current revision (for E6, that means E6(R3), not the 1996 original used in the example) and the date of the Step 4 version you relied on.

ICH guidelines and Kivo

Kivo is a compliant document, content and process management platform for life sciences teams, and it is built to support ICH best practices in day-to-day work. Kivo includes over 450 pre-formatted ICH templates, including ICH M11 clinical protocol templates, authored natively in Microsoft Word. Kivo's eTMF is aligned to the TMF Reference Model, and the eCTD Viewer in Kivo RIM supports eCTD 4.0 for reviewing submissions. For help assembling submission-ready content, see our regulatory submission software.

If you have questions about how to conform to ICH standards, reach out to our team at any time.

Frequently asked questions

What are the four categories of ICH guidelines?

ICH groups its guidelines into Quality (Q), Safety (S), Efficacy (E) and Multidisciplinary (M). Quality covers manufacturing and product quality, Safety covers nonclinical testing, Efficacy covers clinical trial design, conduct and reporting, and Multidisciplinary covers cross-cutting topics such as MedDRA, the Common Technical Document and electronic standards.

What is the current version of ICH E6?

The current version is ICH E6(R3). According to ICH, the Principles and Annex 1 reached Step 4 on 6 January 2025, introducing a flexible, risk-based framework for interventional trials, and Annex 2 was adopted on 3 June 2026. It updates the earlier E6(R2) version that many teams worked to for years.

Are ICH guidelines legally binding?

Not on their own. ICH cannot enforce its guidelines, but regulators such as the FDA and the European Commission implement them through their own regulations and guidance, and ICH tracks each regulator's implementation status and date. Ignoring an implemented guideline can raise concerns during an inspection or application review.

Which ICH guidelines cover the Common Technical Document?

The Common Technical Document is covered by the M4 guideline, which organizes registration dossiers into quality, safety and efficacy parts. Its electronic version, the eCTD, is covered by M8, which includes eCTD v4.0. Both sit in the Multidisciplinary series rather than in Quality, Safety or Efficacy.

What an Integrated QMS, eTMF, and Regulatory Platform Needs

TL;DR: An integrated QMS, eTMF, and regulatory platform needs a shared document core, a single audit trail, and one permissioning model spanning all three functions — not three point...

14 October 2026
5 min read

Aligning eTMF With the CDISC TMF Reference Model

Aligning eTMF With the CDISC TMF Reference Model

An eTMF pharma system aligning with the CDISC TMF Reference Model organizes trial documents into the model's standard zones and artifacts —...

14 October 2026
13 min read

What It Takes to Validate an In-House eTMF System

How do you validate an in-house eTMF system? Validation means producing documented evidence that the system reliably creates, protects, and retrieves trial records exactly as it's supposed...

7 October 2026
6 min read

What an Integrated QMS, eTMF, and Regulatory Platform Needs

TL;DR: An integrated QMS, eTMF, and regulatory platform needs a shared document core, a single audit trail, and one permissioning model spanning all three functions — not three point...

14 October 2026
5 min read

Aligning eTMF With the CDISC TMF Reference Model

Aligning eTMF With the CDISC TMF Reference Model

An eTMF pharma system aligning with the CDISC TMF Reference Model organizes trial documents into the model's standard zones and artifacts —...

14 October 2026
13 min read

What It Takes to Validate an In-House eTMF System

How do you validate an in-house eTMF system? Validation means producing documented evidence that the system reliably creates, protects, and retrieves trial records exactly as it's supposed...

7 October 2026
6 min read